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Background: Serum KL-6 is a useful biomarker for the diagnosis of interstitial lung diseases (ILD). However, KL-6 has
not been used to discriminate different types of ILD. Serum KL-6 concentrations can vary depending on antigen
exposure levels in patients with hypersensitivity pneumonitis (HP); however, seasonal changes in serum KL-6
concentrations in ILD have not been determined. We hypothesized that seasonal variation of serum KL-6 is greater
in HP than for the other ILD. The aim of this study was to determine seasonal variation of serum KL-6 concentrations in
various ILD.
Methods: Serum KL-6 concentrations in the summer season from June 1 to September 30 and the winter season from
November 1 to February 28 were retrospectively analyzed in patients with idiopathic pulmonary fibrosis (IPF, n = 16),
non-specific interstitial pneumonia (NSIP, n = 16), collagen vascular disease-associated interstitial pneumonia (CVD-IP,
n = 33), house-related HP (House-HP, n = 9), bird-related HP (Bird-HP, n = 9), and combined pulmonary fibrosis and
emphysema (CPFE, n = 13).
Results: Bird-HP and House-HP showed greater seasonal serum KL-6 variation than the other ILD. Serum KL-6
concentrations in Bird-HP were significantly increased in the winter and KL-6 concentrations in House-HP were
significantly increased in the summer. Serum KL-6 variation was significantly greater in acute HP than chronic HP.
Receiver operating characteristic curve analysis revealed that greater seasonal variation in serum KL-6 concentrations is
diagnostic for Bird-HP.
Conclusion: HP should be considered in ILD with greater seasonal changes in serum KL-6 concentrations.
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Krebs von den Lungen-6 (KL-6) is a high molecular
weight sialylated MUC1 glycoprotein expressed on type
II pneumocytes and bronchial epithelia. In particular, re-
generating type II pneumocytes in patients with intersti-
tial lung diseases (ILD) highly express KL-6 [1]. KL-6
may increase in sera after enhanced permeability following
destruction of alveolar-capillary barriers and increased
production of KL-6 by regenerating type II pneumocytes.
Thus, serum KL-6 is increased in patients with ILD with
alveolar damage and regeneration of type II pneumocytes,
but not increased in patients with bacterial pneumonia* Correspondence: honi@kochi-u.ac.jp
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unless otherwise stated.[2]. Serum concentrations of KL-6 have been reported
to serve as a sensitive biomarker for the diagnosis and
monitoring of therapeutic responses in various ILD, in-
cluding idiopathic pulmonary fibrosis (IPF), non-specific
interstitial pneumonia (NSIP), collagen vascular disease-
associated interstitial pneumonia (CVD-IP), hypersen-
sitivity pneumonitis (HP), some types of drug-induced
pneumonitis, pulmonary sarcoidosis, Pneumocystis jiro-
vecii pneumonia (PCP), Cytomegalovirus (CMV) pneu-
monia, and radiation pneumonitis [1-8]. Since KL-6 is
not a disease-specific marker and is increased in various
ILD, the usefulness of KL-6 in the differential diagnosis
among ILD is limited. Serum KL-6 concentrations in pa-
tients with eosinophilic pneumonia or organizing pneu-
monia are usually within normal limits at the time of theirl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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diseases are not treated properly. In addition, higher con-
centrations of serum KL-6 predict a poorer prognosis in
patients with acute exacerbation of IPF, drug-induced
pneumonitis, and adult respiratory distress syndrome
[4,7-9]. We occasionally observed unexpected increases
in serum KL-6 concentrations in patients with ILD dur-
ing their clinical course. Possible causes of unexpected
serum KL-6 elevation in patients with ILD include acute
exacerbation of ILD, exacerbation of HP by increased
antigen exposure, the development of PCP, CMV pneu-
monia, drug-induced pneumonitis, or adenocarcinoma
of lung, breast, pancreas, ovary, colon and liver.
HP is an extrinsic allergic alveolitis caused by type III
and type IV hypersensitivity reactions to inhaled organic
antigens such as fungi, bacteria, avian antigens, and fea-
ther duvets [10,11]. HP is classified into acute, subacute,
and chronic forms, although the subacute form might be
a variant of acute HP. Acute HP develops in response to
immune complex formation, and the chronic form is
mediated by Th1 and likely Th17 CD4+ T cells [10]. The
prevalence and type of HP is highly dependent on geo-
graphical, climatic, occupational differences, and genetic
susceptibility. In Japan, summer type house-related HP
(House-HP) was reported to be most prevalent (about
70%) in acute HP, and about 60% of chronic HP was
bird-related HP (Bird-HP) [12,13]. Some case reports
documented that serum KL-6 concentrations vary in re-
sponse to seasonal changes of antigen exposure levels in
patients with HP [14]. Serum KL-6 concentrations may
not return to normal levels even after chest radiographs
demonstrated improvement following corticosteroids
treatment, but did gradually decrease in parallel with im-
proved diffusion capacity of the lungs, which reflects the
disease activity of alveolitis in HP [15]. However, the sea-
sonal variation in serum KL-6 concentrations in ILD, in-
cluding HP, has not been determined. We hypothesized
that seasonal variation of serum KL-6 concentrations in
patients with HP is greater than for the other ILD. The
aim of this study was to determine the seasonal changes
of serum KL-6 concentrations in various ILD.
Methods
Study subjects
Electronic medical records of patients with registered
diagnoses of ILD who consulted our university hospital
from April 1, 2009 to March 31, 2014 were reviewed by
two pulmonologists. Patients with ILD whose serum KL-6
concentrations were measured at least four times over a
period of six months and more than once in one season
were selected for analysis. We excluded undiagnosed cases
with ILD, ILD cases with lung cancer, drug-induced pneu-
monitis, radiation pneumonitis, PCP, or CMV pneumonia,
each of which has been reported to increase serum KL-6concentrations. The final study population consisted of 96
ILD patients classified as IPF (n = 16), NSIP (n = 16),
CVD-IP (n = 33), House-HP (n = 9), Bird-HP (n = 9), and
combined pulmonary fibrosis and emphysema (CPFE, n =
13), based on diagnostic criteria for each. This study com-
plied with the Declaration of Helsinki. The Ethical Review
Board of the Kochi Medical School, Kochi University,
reviewed the study design and protocol. Approval was
waived according to the Ethical Guideline for Clinical
Research issued by the Ministry of Health, Labour and
Welfare, Japan. Informed consent for the usage of data
had been obtained from all patients at their consulta-
tion and patients who refused were not included in
this study.
Diagnosis of ILD
IPF was clinically diagnosed based on the ATS/ERS/JRS/
ALAT guideline using the presence of basal honeycomb
shadows on the chest high-resolution computed tomog-
raphy (HRCT) (all cases), bronchoalveolar lavage (BAL)
(n = 5), transbronchial lung biopsy (TBLB) (n = 5) and
exclusion of other causes such as NSIP, CVD-IP, HP, and
CPFE [16]. Eight patients with NSIP were histologically
diagnosed based on the ATS/ERS multidisciplinary con-
sensus classification of IIPs with surgical lung biopsy
[17]. Other 8 NSIP patients were clinically diagnosed by
the chest HRCT findings compatible with NSIP pattern,
increased lymphocytosis in BAL fluid, lack of granuloma
in TBLB specimens, and exclusion of IPF, CVD-IP, HP,
or CPFE. CVD-IP was diagnosed based on symptoms,
laboratory findings of CVD, and interstitial shadows on
chest HRCT. HP was diagnosed by combinations of the
presence of specific IgG antibodies against pigeon, bud-
gerigar (Phadia AB, Uppsala, Sweden) for Bird-HP or
Trichosporon asahii for House-HP, spontaneous remis-
sion of interstitial shadows after isolation from causative
antigens, positive results on an environmental provoca-
tion test, bronchoscopic findings including BAL (n = 17),
TBLB (n = 16) and/or surgical lung biopsy (n = 8) [10].
House-HP refers to HP positive for specific IgG antibody
against Trichosporon asahii. BAL samples were obtained
by instillation of 50 ml of saline 3 times and differential
cell numbers were determined at the diagnosis of HP
without treatment. HP was further classified into acute
HP (acute and subacute forms) based on acute onset of
symptoms and the appearance of mainly ground glass
opacities on chest HRCT, or chronic HP based on grad-
ual progression of symptoms and the presence of mainly
interstitial fibrotic shadows on chest HRCT. All cases of
Bird-HP in the present study were related to the use of
feather products. CPFE was diagnosed by the presence
of both emphysematous changes in the upper lobes and
interstitial fibrotic changes in the lower lobes on chest
HRCT, and exclusion of other causes such as CVD-IP, HP,
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cases of NSIP, five cases of CVD-IP, two cases of House-
HP, six cases of Bird-HP, and 12 cases of CPFE were care-
fully observed throughout their clinical courses without
treatment due to patients’ refusal of using pirfenidone,
corticosteroids or immunosuppressants. Environmental
improvement to avoid exposure to causative antigens was
instructed to all patients at the time of their final HP
diagnosis.
Measurement of serum KL-6
Serum samples were collected sequentially from patients
4 to 60 times (median 15 times) during their clinical
course (median 903 days, range 195–1703 days). The fre-
quency and duration of KL-6 measurement was not dif-
ferent among each group of ILD (Table 1). Serum KL-6
concentrations were measured by the chemiluminescentTable 1 Seasonal variation of serum KL-6 concentrations in v
Total IPF NSIP
n 96 16 16
Numbers of BAL/TBLB/SLB 55/50/18 4/4/0 14/13/8
Age 68 (11) 71 (14) 71 (12)
Sex (Female) 41 3 9
No treatment 32 2 5
Duration of KL-6 measurement 903 (682) 1013 (670) 718 (326)
Frequency of KL-6 measurement 15 (17) 13 (20) 16 (9)
Kmax 1264 (1182) 1620 (891) 1622 (1734)
Kmin 532 (349) 667 (335) 590 (328)
Kmax-Kmin 686 (958) 793 (510) 1140 (1550)
Kmax/Kmin 2.46 (1.77) 2.09 (1.02) 3.06 (2.84)
Smax 918 (769) 1231 (548) 1155 (1258)
Smin 588 (390) 696 (347) 715 (293)
Smax-Smin 345 (580) 291 (856) 416 (1075)
Smax/Smin 1.61 (1.05) 1.49 (1.13) 1.54 (1.58)
Wmax 1105 (875) 1320 (799) 1148 (646)
Wmin 616 (413) 763 (581) 616 (276)
Wmax-Wmin 392 (629) 327 (467) 495 (880)
Wmax/Wmin 1.65 (0.78) 1.46 (0.63) 1.80 (0.86)
Smax-Wmax −51 (511) −116 (581) 5 (632)
Smax/Wmax 0.93 (0.46) 0.88 (0.44) 1.01 (0.57)
Smin-Wmin −50 (181) −135 (281) 22 (139)
Smin/Wmin 0.90 (0.27) 0.82 (0.27) 1.04 (0.21)
The maximum and minimum concentrations of serum KL-6 throughout each patie
concentrations during the summer (June 1 - September 30) were defined as Smax
February 28) as Wmax or Wmin. IPF, idiopathic pulmonary fibrosis; NSIP, non-speci
pneumonia; House-HP, house-related hypersensitivity pneumonitis; Bird-HP, bird-re
emphysema; BAL, bronchoalveolar lavage; TBLB, transbronchial lung biopsy; SLB, s
*P < 0.0033 vs IPF.
#P <0.0033 vs NSIP.
†P < 0.0033 vs CVD-IP.
‡P <0.0033 vs House-HP.
§P <0.0033 vs Bird-HP.enzyme immunoassay LUMIPULSE KL-6 using a KL-6
antibody (EIDIA Co., Ltd, JPN). The cut-off value for
serum KL-6 was set at 435 U/ml according to the manu-
facturer’s instructions. The maximum or minimum con-
centrations of serum KL-6 in each patient’s clinical course
was defined as Kmax or Kmin, respectively. Similarly,
serum KL-6 concentrations during the summer from June
1 to September 30 was defined as Smax or Smin, and
serum KL-6 concentrations during the winter from No-
vember 1 to February 28 as Wmax or Wmin. The vari-
ation of serum KL-6 concentrations over each patient’s
clinical course (Kmax-Kmin or Kmax/Kmin), during the
summer (Smax-Smin or Smax/Smin), during the winter
(Wmax-Wmin or Wmax/Wmin), and seasonal changes in
serum KL-6 concentrations between summer and win-
ter (Smax-Wmax, Smax/Wmax, Smin-Wmin, or Smin/
Wmin) were retrospectively analyzed.arious interstitial lung diseases
CVD-IP House-HP Bird-HP CPFE P value
33 9 9 13 -
20/17/2 8/7/5 9/9/3 0/0/0 -
64 (10)* 71 (20) 71 (6) 70 (8) 0.007
23* 3 3 0#† <0.001
5 2 6*† 12*#†‡ <0.001
1097 (629) 569 (385) 605 (564) 819 (750) 0.072
22 (23) 17 (12) 11 (6) 9 (10) 0.133
993 (1002) 2157 (2162) 1761 (2110) 925 (384)# 0.004
433 (287)* 451 (627) 489 (382) 483 (263) 0.070
633 (769) 1173 (1249) 1449 (1467) 360 (216)#§ 0.001
2.47 (1.21) 3.98 (4.11) 4.13 (3.09) 1.95 (0.67)§ 0.002
885 (807) 1932 (1910) 847 (639) 770 (294) 0.090
438 (313)* 451 (615) 594 (549) 503 (290) 0.033
406 (432) 1002 (1310) 236 (176) 174 (292) 0.072
1.76 (0.93) 3.68 (3.63) 1.31 (0.46)‡ 1.35 (0.66) 0.047
878 (763) 649 (1756) 1572 (1008)† 905 (434) 0.012
525 (328)* 491 (855) 750 (687) 551 (380) 0.073
259 (489) 252 (1120) 839 (721)† 342 (173) 0.051
1.44 (0.72) 1.47 (0.53) 2.78 (2.34) 1.82 (0.69) 0.078
−17 (288) 353 (668) −819 (609)#†‡ −179 (275)§ 0.001
0.96 (0.31) 1.43 (2.31) 0.47 (0.21)*#†‡ 0.82 (0.30)‡§ <0.001
−62 (114) −42 (310) −79 (197) −54 (206) 0.066
0.87 (0.21) 0.89 (0.20) 0.81 (0.31) 0.89 (0.26) 0.099
nt’s clinical course was defined as Kmax and Kmin. Similarly, serum KL-6
or Smin, and serum KL-6 concentrations during the winter (November 1 –
fic interstitial pneumonia; CVD-IP, collagen vascular disease-related interstitial
lated hypersensitivity pneumonitis; CPFE, combined pulmonary fibrosis and
urgical lung biopsy. Data are expressed as the median (interquartile range).
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Data are presented as the median (interquartile range).
Statistical analysis of data was performed using IBM
SPSS Statistics version 19 for Windows (IBM Corp, NY,
USA). The comparisons of serum KL-6 concentrations
among ILD were tested by the Kruskal-Wallis test. Diffe-
rences in serum KL-6 concentrations between two groups
were evaluated by the two-tailed Mann–Whitney U-test.
Serum KL-6 concentrations and KL-6 ratios were further
analyzed using receiver operating characteristic (ROC)
curves to determine the cut-off levels that resulted in
the optimal diagnostic accuracy for the diagnosis of HP,
House-HP or Bird-HP. Quantitative differences were tes-
ted by the Pearson’s chi-square test for goodness of fit or
the Fisher’s exact probability test. A P-value of < 0.05 was
considered statistically significant. The Holm’s sequential
Bonferonni correction was used to adjust the levels of sig-
nificance for multiple comparisons.
Results
Patient characteristics
Patients with CVD-IP were significantly younger than
patients with IPF (Table 1). Patients with CVD-IP (23
out of 33) and NSIP (9 out of 16) were predominantly
female, and all cases with CPFE were male. Four cases
with IPF and one case with NSIP had acute exacerbation
during their clinical course [842 (527) days], and two
cases of IPF and one case of NSIP were deceased.
Serum KL-6 concentrations in various ILD
The maximum KL-6 concentrations over the patients’
clinical courses (Kmax) were significantly higher in pa-
tients with NSIP compared to CPFE (Table 1, Figure 1A).
The minimum KL-6 (Kmin) was significantly higher in
patients with IPF than with CVD-IP. The variation of
serum KL-6 concentrations over their clinical courses
(Kmax-Kmin or Kmax/Kmin) was significantly greater
in patients with Bird-HP than with CPFE (Table 1,
Figure 1B). The variation of KL-6 during the summer
(Smax/Smin) in patients with House-HP was signifi-
cantly greater than Bird-HP (P = 0.003) and showed a
tendency to be greater than CPFE (P = 0.004), CVD-
IP (P = 0.021), IPF (P = 0.033), or NSIP (P = 0.037)
(Table 1, Figure 1C). The maximum KL-6 concentrations
during the winter (Wmax) and Wmax-Wmin were signifi-
cantly higher in patients with Bird-HP than CVD-IP
(Table 1, Figure 1D).
Seasonal variation of serum KL-6 concentrations in
different ILD
It is particularly noteworthy that Bird-HP and House-HP
showed significantly greater seasonal changes in serum
KL-6 concentrations than the other ILD. Serum KL-6 con-
centrations between the summer and the winter (Smax-Wmax or Smax/Wmax) were greater in patients with
House-HP than Bird-HP (P < 0.001) or CPFE (P = 0.003)
(Table 1, Figure 2A). Smax/Wmax in patients with Hosue-
HP showed a tendency to be greater than IPF (P = 0.008)
or CVD-IP (P = 0.01). Eight out of nine patients (88.9%)
with Bird-HP showed greater increases in serum KL-6
concentrations in the winter compared to the summer; as
such, Smax-Wmax in patients with Bird-HP showed ne-
gative values and Smax-Wmax or Smax/Wmax was sig-
nificantly lower than the other ILD (Table 1, Figure 2A).
These data suggest that serum KL-6 concentrations were
significantly increased in the summer in patients with
House-HP or in the winter in patients with Bird-HP.
Typical examples of sequential seasonal changes in serum
KL-6 concentrations in a patient with House-HP who had
a specific IgG antibody against Trichosporon asahii and in
a patient with Bird-HP related to the usage of a feather
pillow are shown in Figure 2B and C, respectively. Corti-
costeroids were not administered to these patients be-
cause of patients’ refusal. Serum KL-6 concentrations in
the patient with House-HP were significantly increased in
the summer season and gradually decreased after environ-
mental improvement and cleaning her house of fungi,
but increased again in the next year when fungi regrew
(Figure 2B). Serum KL-6 concentrations in the patient
with Bird-HP were significantly increased in the winter
but gradually decreased in the summer. She ceased com-
ing to the hospital twice because her symptoms had im-
proved naturally. She never used feather duvets, but a
feather pillow that she used during a nap in the winter
was finally proven to be the cause (Figure 2C).
Variation of serum KL-6 concentrations in acute or
chronic HP
In general, serum KL-6 concentrations are thought to be
higher in acute HP compared to chronic HP. Kmax in
patients with acute HP (n = 12) was significantly higher
than that in chronic HP (n = 6) [2635 (1678) for acute
HP vs 1036 (402) for chronic HP, P = 0.024]. Kmax-
Kmin was also significantly higher in patients with acute
HP than chronic HP (1883 (883) for acute HP vs 683
(81) for chronic HP, P = 0.005, Figure 2D). These results
confirm that variations in serum KL-6 concentrations
were significantly greater in acute HP than chronic HP.
There is no difference in lymphocytosis between acute
HP [48.0 (55.1) %] and chronic HP [18.4 (5.6) %], and no
correlation between serum KL-6 concentrations at the
same day of BAL and lymphocytosis in BAL fluid.
Diagnostic value of serum KL-6 concentrations and KL-6
ratios in HP
ROC curves were used to evaluate the diagnostic value
of KL-6 concentrations or KL-6 ratios for the diagnosis






Figure 1 Serum KL-6 concentrations in various interstitial lung diseases (ILD). (A) The maximum concentrations of serum KL-6 during their
clinical courses (Kmax) in patients with various interstitial lung diseases (ILD). (B) The ratio of maximum and minimum concentrations of serum
KL-6 (Kmax/Kmin) in various ILD. (C) The ratio of maximum and minimum concentrations of serum KL-6 in the summer (Smax/Smin) in various
ILD. (D) The maximum concentrations of serum KL-6 in the winter (Wmax) in various ILD. IPF, idiopathic pulmonary fibrosis; NSIP, non-specific
interstitial pneumonia; CVD-IP, collagen vascular disease-related interstitial pneumonia; House-HP, house-related hypersensitivity pneumonitis,
Bird-HP; bird-related hypersensitivity pneumonitis, CPFE; combined pulmonary fibrosis and emphysema. *P < 0.0033 vs IPF, #P < 0.0033 vs NSIP,
†P < 0.0033 vs CVD-IP, ‡P < 0.0033 vs House-HP, §P < 0.0033 vs Bird-HP.
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the curve with 0.878 (Table 2, Figure 3), indicating mod-
erate accuracy. When the Smax/Wmax cut-off level was
set at less than 0.61 based on the highest Youden’s in-
dex, the sensitivity, specificity, diagnostic accuracy and
likelihood ratio for the diagnosis of Bird-HP were 77.8%,
92.7%, 91.2% and 10.63, respectively. These results sug-
gest that seasonal variation of serum KL-6 concentra-
tions is useful for the differential diagnosis of Bird-HP.
Discussion
We evaluated seasonal variations in serum KL-6 con-
centrations in various ILD, including IPF, NSIP, CVD-IP,
HP, and CPFE, and confirmed that seasonal changes of
serum KL-6 concentrations were greater in HP especially
Bird-HP than for the other ILD. We also found that var-
iations in serum KL-6 concentrations were significantlygreater in acute HP than in chronic HP. Furthermore,
seasonal variation of KL-6 concentrations was differ-
entially diagnostic for distinguishing Bird-HP from the
other ILD.
Bird-HP and House-HP exhibited increased serum KL-6
concentrations in the winter and summer seasons, res-
pectively. These seasonal differences usually depend on
the differences in living environment and patient lifestyles.
However, it should be noted that House-HP may be exac-
erbated not only in the summer but also during the winter
season as house heating, increased humidifier usage [19],
and improved air tightness of the house may cause mold
to spread even in the winter. Also, Bird-HP may be im-
proved even in the winter by removing bird-related prod-
ucts or quit breeding. Therefore, physicians should remain
vigilant for possible HP, and detailed history taking is very

































Figure 2 Seasonal variation of serum KL-6 concentrations in various ILD. (A) The ratio of maximum concentrations of summer and winter
serum KL-6 concentrations (Smax/Wmax) in various ILD. Seasonal changes in serum KL-6 concentrations in a patient with House-HP who had a
specific IgG antibody against Trichosporon asahii (B) and in a patient with Bird-HP related to feather pillow use (C). The duration when the patient
did not refer to the hospital was shown by dot line in Figure 2C. Corticosteroids were not administered to either patient because of patients’
refusal. The open and closed squares over the figure indicate the summer and winter seasons, respectively. (D) Variations of maximal and minimal
serum KL-6 concentrations (Kmax-Kmin) in patients with acute HP and chronic HP.
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Correct, early-stage diagnosis of HP is crucial, since chro-
nic HP can result in a fatal outcome if exposure to the
causative antigen is continued [20]. However, differential
diagnosis of chronic HP from the other ILD is difficult by
only history taking and chest HRCT imaging in clinical
settings. Chest HRCT results from chronic HP and IPF
patients were similar and difficult to discriminate only by
chest HRCT imaging [21,22]. We experienced a case with
clinically diagnosed IPF based on chest HRCT findings,
histological findings of surgical lung biopsy and detailedTable 2 Diagnostic value of KL-6 concentrations and KL-6 rat
House-HP, and Bird-HP




HP vs non-HP Kmax 0.681 0.017 0.316 2
Kmax-Kmin 0.744 0.001 0.427 6
Kmax/Kmin 0.757 0.001 0.436 3
House-HP vs non-House-HP Smax-Wmax 0.774 0.007 0.472 1
Smax/Wmax 0.802 0.003 0.461 1
Bird-HP vs non-Bird-HP Smax-Wmax 0.842 0.001 0.706 −
Smax/Wmax 0.878 <0.001 0.705 0
Cut-off value of Smax-Wmax and Smax/Wmax for the diagnosis of Bird-HP was lesshistory taking but without the usage of feather duvets; the
case was finally found to be HP when interstitial shadows
were exacerbated after usage of feather duvets by a partner
but not by the patient. There is little therapeutic benefit
by administering pirfenidone or N-acetyl cysteine to IPF
patients [17]. Identifying HP from cases misdiagnosed as
IPF is very important because avoidance of the causative
antigen is crucial for improving the clinical outcome in
HP patients. The best therapy for HP is isolation from
causative antigens, improvement of the living environ-
ment, and/or systemic administration of corticosteroidsios for the diagnosis of hypersensitivity pneumonitis (HP),
ut-off
alue




532 44.4 87.2 79.2 3.47
54 88.9 53.8 60.4 1.93
.15 66.7 76.9 75.0 2.89
96 66.7 80.5 79.1 3.42
.08 77.8 68.3 69.2 2.45
328 88.9 81.7 82.4 4.86
.61 77.8 92.7 91.2 10.63
than −328 and 0.61, respectively. AUC; area under the curve.
1.0
Figure 3 Receiver operating characteristic curve of Smax/Wmax
for the diagnosis of Bird-HP.
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presence of seasonal changes of KL-6 concentrations in
each patient, but not comparing KL-6 concentration
among patients, is clinically important for suspecting
the possibility of HP.
We confirmed that variations in serum KL-6 con-
centrations were significantly greater in acute than in
chronic HP, which may reflect the responses to the dif-
ferent levels of inhaled antigen exposure and the degree
of alveolitis. In general, alveolitis with lymphocytosis
seems to be less in chronic than acute HP, as lympho-
cytosis in BAL fluid was less in chronic than acute or
subacute HP [23]. However, there is no difference in
lymphocytosis between acute HP and chronic HP, and
no correlation between serum KL-6 concentrations and
lymphocytosis in BAL fluid in the present study, sug-
gesting that increased serum KL-6 concentrations are
unlikely to be related to alveolitis with lymphocytosis.
Serum KL-6 concentrations are thought to be related to
alveolar damage and increased production of KL-6 by
regenerating type II pneumocytes. As most cases with
acute HP did not undergo surgical lung biopsy, diffe-
rences in regenerating type II pneumocytes between
acute HP and chronic HP were difficult to evaluate. In-
creased numbers of reactive type II pneumocytes in BAL
fluids in patients with HP are reported as similar to PCP
and drug-induced pneumonitis [24]. However, differ-
ences in regenerating type II pneumocytes between
acute HP and chronic HP have not yet been examined.
The limitations of this study include the small number
of study subjects, especially for HP, our retrospective ap-
proach, lack of seasonal environmental data collection,and the differences in the treatments among the ILD
patients, which may affect serum KL-6 concentrations.
However, a prospective study to determine the seasonal
variation in serum KL-6 concentrations in ILD without
treatment is difficult to set up because of ethical issues.
Therefore, we decided to use a retrospective study de-
sign to address the hypothesis that HP may have greater
seasonal serum KL-6 variation than the other ILD. Al-
though small numbers of HP patients were included in
the present retrospective study, we clearly demonstrated
that Bird-HP and House-HP showed significantly greater
seasonal variation in serum KL-6 concentrations com-
pared with the other ILD. Moreover, seasonal variation
of serum KL-6 determined by Smax/Wmax less than
0.61 may be useful for the differential diagnosis of Bird-
HP. Although we did not collect seasonal environmental
data to establish the direct link between seasonal change
of KL-6 concentrations and antigen exposure levels, we
searched environment of each patients’ house and near-
by and found mold spread during summer in the house
of patients with House-HP or increased usage of feather
products during winter in patients with Bird-HP and
therefore speculated that increased antigen exposure
could be the cause of seasonal changes in serum KL-6
concentrations.Conclusions
Serum KL-6 concentrations exhibited significant seasonal
variation presumably in response to seasonal fluctuating
antigen exposure levels in patients with HP. Variations in
serum KL-6 concentrations were significantly greater in
acute HP than in chronic HP. It is necessary to consider
the possibility of HP when unexpected seasonal changes
in serum KL-6 concentrations are found during the cli-
nical course of ILD.Abbreviations
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